振德醫療(603301.SH)控股股東減持振德轉債44萬張
格隆匯1月17日丨振德醫療(603301.SH)公佈,經中國證券監督管理委員會《關於核准振德醫療用品股份有限公司公開發行可轉換公司債券的批覆》核准,公司於2019年12月公開發行可轉換公司債券(以下簡稱“振德轉債”)440萬張(人民幣4.4億元),期限6年。其中公司控股股東浙江振德及實際控制人沈振芳合計配售振德轉債259.6萬張(人民幣2.596億元),佔本次可轉換公司債券發行總量的59.00%。
2020年1月14日,控股股東及實際控制人沈振芳女士合計減持振德轉債44萬張,佔本次可轉換公司債券發行總量的10.00%。
公司於2020年1月17日接到控股股東通知,2020年1月17日,控股股東浙江振德通過上海證券交易所交易系統減持振德轉債44萬張,佔本次可轉換公司債券發行總量的10.00%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.